moderated NATAP/IDWeek: Doravirine-Rational Design Review

Jules Levin
                                    IN THIS NEW POZ List ALL pictures/tables are shown only at the very bottom of email report….

Rational Design of Doravirine (DOR): A Review of Development From Bench to Patients

 Merck has ongoing clinical study of 2-ART drug regimen combining doravirine with only long-acting MK8591 their new nuke-type of ART but different, and could also be a long-acting PrEP.

It has been recruiting & is ongoing: Not Yet Recruiting New: MK-8591 With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)

reported at IDWeek:

 IDWeek: Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial - (10/06/18)

Reported by Jules Levin

IDWeek; San Francisco, CA; October 3–7, 2018


Carey Hwang, MD, PhD; Ming-Tain Lai, PhD; Daria Hazuda, PhD

Merck & Co., Inc., Kenilworth, NJ, USA

poster pdf

Reprinted with permission from Feng M, et al. Antimicrob Agents Chemother. 2015;59(1):590-598 

NATAP natapdoctors mailing list -- natapdoctors@...

This is an annoucement-only mailing list.  Do not reply.

To unsubscribe: send a blank email to natapdoctors-request@... with a subject of unsubscribe.

For more information, see